HDACi: The Columbus' Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
- PMID: 36358670
- PMCID: PMC9654569
- DOI: 10.3390/cancers14215251
HDACi: The Columbus' Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
Abstract
Histone deacetylases (HDACs) are a group of enzymes that modify gene expression through the lysine acetylation of both histone and non-histone proteins, leading to a broad range of effects on various biological pathways. New insights on this topic broadened the knowledge on their biological activity and even more questions arose from those discoveries. The action of HDACs is versatile in biological pathways and, for this reason, inhibitors of HDACs (HDACis) have been proposed as a way to interfere with HDACs' involvement in tumorigenesis. In 2006, the first HDACi was approved by FDA for the treatment of cutaneous T-cell lymphoma; however, more selective HDACis were recently approved. In this review, we will consider new information on HDACs' expression and their regulation for the treatment of central and peripheral nervous system diseases.
Keywords: HATs; HDAC inhibitors; HDAC5; HDAC6; HDACs; central nervous system; nervous system; neurons; peripheral nervous system.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
The emerging roles of HDACs and their therapeutic implications in cancer.Eur J Pharmacol. 2022 Sep 15;931:175216. doi: 10.1016/j.ejphar.2022.175216. Epub 2022 Aug 18. Eur J Pharmacol. 2022. PMID: 35988787 Review.
-
Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.J Proteomics. 2018 Sep 15;187:126-143. doi: 10.1016/j.jprot.2018.07.003. Epub 2018 Jul 18. J Proteomics. 2018. PMID: 30012418
-
Histone deacetylase inhibitors selectively suppress expression of HDAC7.Mol Cancer Ther. 2007 Sep;6(9):2525-34. doi: 10.1158/1535-7163.MCT-07-0251. Mol Cancer Ther. 2007. PMID: 17876049
-
Effects of novel HDAC inhibitors on urothelial carcinoma cells.Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y. Clin Epigenetics. 2018. PMID: 30064501 Free PMC article.
-
Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.Cancers (Basel). 2019 Jun 19;11(6):850. doi: 10.3390/cancers11060850. Cancers (Basel). 2019. PMID: 31248188 Free PMC article. Review.
Cited by
-
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.Pharmaceuticals (Basel). 2025 Feb 27;18(3):341. doi: 10.3390/ph18030341. Pharmaceuticals (Basel). 2025. PMID: 40143119 Free PMC article. Review.
-
Repurposing Histone Deacetylase Inhibitors for Management of Solid Organ Transplant Rejection.Results Probl Cell Differ. 2025;75:309-328. doi: 10.1007/978-3-031-91459-1_11. Results Probl Cell Differ. 2025. PMID: 40593215 Review.
-
Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells.Front Pharmacol. 2023 Sep 28;14:1275833. doi: 10.3389/fphar.2023.1275833. eCollection 2023. Front Pharmacol. 2023. PMID: 37841928 Free PMC article.
-
LMK-235 suppresses osteoclastogenesis and promotes osteoblastogenesis by inhibiting HDAC4.Sci Rep. 2024 Aug 28;14(1):19973. doi: 10.1038/s41598-024-70814-8. Sci Rep. 2024. PMID: 39198677 Free PMC article.
-
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.Nat Commun. 2025 Aug 25;16(1):7919. doi: 10.1038/s41467-025-62934-0. Nat Commun. 2025. PMID: 40855049 Free PMC article.
References
-
- Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovás L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources